澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

IMUGENE LTD

0.315

0.000

成交量：92.43萬

成交額：28.71萬

市值：9,932.79萬

市盈率：-1.00

高：0.320

開：0.310

低：0.305

收：0.315

52周最高：1.598

52周最低：0.245

股本：3.15億

流通股本：2.54億

量比：0.94

換手率：0.36%

股息：- -

股息率：- -

每股收益(TTM):-0.316

每股收益(LYR):-0.316

淨資產收益率：-84.54%

總資產收益率：-37.27%

市淨率：2.21

市盈率(LYR):-1.00

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股-0.33%

資金流向

資金流入：

資金流出：

新聞資訊

IMUGENE LTD與JW Therapeutics宣佈開展合作，以推進Oncarlytics與Carteyva®的結合治療實體腫瘤

免疫基因向澳洲證交所提交證券報價申請

IMUGENE LTD將舉辦Azer-cel新數據線上説明會

华尔街洞察

BUZZ-澳大利亞Imugene因折價配售股價暴跌

华尔街洞察

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/IMU.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.315,"timestamp":1766466720000,"preClose":0.315,"halted":0,"volume":924340,"delay":0,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":315326785,"eps":-0.315594,"marketStatus":"已收盤","change":0,"latestTime":"12-23 16:12:00 AEDT","open":0.31,"high":0.32,"low":0.305,"amount":287146,"amplitude":0.047619,"askPrice":0.315,"askSize":242007,"bidPrice":0.31,"bidSize":29497,"shortable":3,"etf":0,"ttmEps":-0.315594,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1766530800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.315,"openAndCloseTimeList":[[1766444400000,1766466000000]],"volumeRatio":0.937437,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-37.27%","roe":"-84.54%","lyrEps":-0.315594,"volumeRatio":0.937437,"shares":315326785,"dividePrice":0,"high":0.32,"amplitude":0.047619,"preClose":0.315,"low":0.305,"week52Low":0.245,"pbRate":"2.21","psRate":"22.59","week52High":1.598,"institutionHeld":0,"latestPrice":0.315,"committee":-0.782714,"eps":-0.315594,"divideRate":0,"volume":924340,"delay":0,"ttmEps":-0.315594,"open":0.31,"prevYearClose":1.258,"prevWeekClose":0.305,"prevMonthClose":0.345,"prevQuarterClose":0.305,"fiveDayClose":0.315,"twentyDayClose":0.315,"sixtyDayClose":0.305},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1101701814","title":"IMUGENE LTD與JW Therapeutics宣佈開展合作，以推進Oncarlytics與Carteyva®的結合治療實體腫瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1101701814","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101701814?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 13:01","pubTimestamp":1764306070,"startTime":"0","endTime":"0","summary":"IMUGENE LTD与JW Therapeutics宣布开展合作，以推进Oncarlytics与Carteyva®的结合治疗实体肿瘤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"1155449886","title":"免疫基因向澳洲證交所提交證券報價申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1155449886","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155449886?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 14:42","pubTimestamp":1752648148,"startTime":"0","endTime":"0","summary":"澳大利亚生物技术企业Imugene Limited于今日正式向澳大利亚证券交易所递交证券报价申请文件。此举标志着该公司资本运作进入新阶段，市场关注其后续流动性变化可能带来的投资机会。根据披露流程，该申请需经交易所合规部门审核。若获批准，IMU普通股将获得持续报价资格，有助于提升二级市场交易活跃度。IMU股价近三个月累计上涨27%，跑赢ASX全普通指数15个百分点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"1101643828","title":"IMUGENE LTD將舉辦Azer-cel新數據線上説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=1101643828","media":"华尔街洞察","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101643828?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 11:11","pubTimestamp":1752635482,"startTime":"0","endTime":"0","summary":"生物技术企业IMUGENE LTD宣布即将召开专题线上会议，重点展示其核心候选疗法Azer-cel的最新临床进展。此次会议将披露该细胞治疗产品在血液肿瘤领域的关键数据集，涵盖治疗响应率、安全特性及作用机制等核心维度。作为靶向CD19的CAR-T疗法，Azer-cel采用创新基因编辑技术以增强抗肿瘤活性。IMUGENE LTD首席执行官强调：\"这些数据标志着我们在实体瘤治疗领域迈出重要一步，为推进后期临床试验奠定了坚实基础。此次数据披露或将影响市场对该企业估值预期的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"1178224095","title":"BUZZ-澳大利亞Imugene因折價配售股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1178224095","media":"华尔街洞察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178224095?lang=zh_tw&edition=fundamental","pubTime":"2025-07-16 10:35","pubTimestamp":1752633338,"startTime":"0","endTime":"0","summary":"Imugene股票今日盘中重挫，一度暴跌18.8%至0.345澳元，创下7月2日以来新低；最终收跌11.8%，报0.375澳元。每股0.33澳元的发行价较7月11日收盘价折价22.4%，突显了市场对折价融资的负面反应。公司还计划通过股票购买计划额外融资1500万澳元，发行价相同。Azer-cel是一种同种异体CAR T细胞疗法，专为治疗复发或难治性弥漫性大B细胞淋巴瘤设计。今日交易量激增至170万股，是30天平均水平的2.9倍。年内迄今，该股已暴跌70.2%，计入今日跌幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMU.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.003303}]}}